
Sign up to save your podcasts
Or
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
4.7
1919 ratings
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
291 Listeners
314 Listeners
48 Listeners
861 Listeners
492 Listeners
14 Listeners
90 Listeners
25 Listeners
513 Listeners
132 Listeners
349 Listeners
183 Listeners
365 Listeners
5 Listeners
79 Listeners